In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
The trial tested six injectable doses and three oral doses over as long as 36 weeks
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
_256_384.jpg)
The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Subscribe To Our Newsletter & Stay Updated
